Press Releases

· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that it has received Clinical Trial Application (...

Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that Ondo Finance ("Ondo") has launched ENLVon, the Ondo tokenized representation of ENLV's ordinary shares on Ondo's Global Markets platform. Through the launch of ENLVon, non-U.S. retail and instit...

According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction markets via the Rain ...

Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; "Enlivex" or "the Company") today reported financial results and business highlights for the year ended December 31, 2025. Net income for the year ended December 31, 2025 was $1.23 Billion and diluted earnings per ordinary share (EPS) was $25.48...

$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investorThe Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22, 2026, for a total aggregate purchase amount of $10 million...